EXA-CEL/CASGEVY - a gene editing therapy

The MHRA (The Medicines and Healthcare products Regulatory Agency) approved the safety of this treatment in November 2023, offering hope and optimism to the sickle cell community. But on the 14th March 2024, NICE published a draft decision NOT to recommend exa-cel/casgevy therapy for NHS funding, and opened up a consultation process. The deadline was on 11th April 2024.

Sickle cell patients, their families, advocacy groups, The Anthony Nolan project and The Sickle Cell Society were some of the groups who responded. 

On the 8th May 2024, NICE will review the consultations and have a second committee reading. The final publication will be on the 17th July 2024.

https://www.nice.org.uk/guidance/indevelopment/gid-ta11249